Wyeth To Revisit Launch Plans For Effexor XR Follow-On
The company is waiting for results of lower dose desvenlafaxine studies, but says launch plans are not impacted by FDA's review extension.
The company is waiting for results of lower dose desvenlafaxine studies, but says launch plans are not impacted by FDA's review extension.